Midostaurin, a multikinase inhibitor that targets FLT3 and other kinases, was approved for the treatment of adult patients with newly diagnosed, FLT3-mutated AML when combined with intensive induction and consolidation chemotherapy [9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.